Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Apocard
2. Flcane
3. Flecadura
4. Flecainid Isis
5. Flecainid-isis
6. Flecainide
7. Flecainide Monoacetate
8. Flecainide Monoacetate, (+-)-isomer
9. Flecainide Monoacetate, (r)-isomer
10. Flecainide Monoacetate, (s)-isomer
11. Flecainide, (r)-isomer
12. Flecainide, (s)-isomer
13. Flecainide, 5-ho-n-(6-oxo)-derivative
14. Flecainide, 5-ho-n-(6-oxo)-derivative, (+-)-isomer
15. Flecatab
16. R818
17. Tambocor
1. 54143-56-5
2. Flecainide (acetate)
3. Tambocor
4. R-818
5. Flecainide Monoacetate
6. Flecainide Acetate Salt
7. R 818
8. 54143-56-5 (acetate)
9. N-(2-piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide Acetate
10. N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
11. Mls000069675
12. Chebi:5091
13. M8u465q1wq
14. Apocard
15. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, Monoacetate
16. Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-,monoacetate
17. N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
18. Smr000058451
19. Acetic Acid;n-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
20. N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Acetate
21. Sr-01000000172
22. Einecs 258-997-5
23. Mfcd00214290
24. Unii-m8u465q1wq
25. Flecainidacetat
26. Tambocor (tn)
27. Flecainide Acetate [usan:usp:jan]
28. N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide Monoacetate
29. Dsstox_cid_626
30. Opera_id_1587
31. 2,5-bis-(2,2,2-trifluoroethoxy)-n-(2-piperidinylmethyl)benzamide Acetate
32. Cas-54143-56-5
33. Dsstox_rid_75700
34. Dsstox_gsid_20626
35. Mls001148177
36. Mls002222300
37. Schembl121583
38. Chembl1200822
39. Dtxsid8020626
40. Flecainide Acetate [jan]
41. Flecainide Acetate (jp17/usp)
42. Flecainide For System Suitability
43. Flecainide Acetate [usan]
44. Flecainide Acetate [vandf]
45. Hms1570c12
46. Hms2097c12
47. Hms2231e15
48. Hms3259f11
49. Hms3267n04
50. Hms3369m07
51. Hms3412d09
52. Hms3676d09
53. Hms3714c12
54. Flecainide Acetate [mart.]
55. 11a-hydroxyepoxyprogesterone
56. Bcp17825
57. Flecainide Acetate [usp-rs]
58. Flecainide Acetate [who-dd]
59. Tox21_200208
60. Akos015889993
61. N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide Acetate
62. Ccg-220735
63. Cs-1400
64. Nc00641
65. Sb19142
66. Flecainide Acetate [ep Impurity]
67. Flecainide Acetate [orange Book]
68. Flecainide Acetate [ep Monograph]
69. Flecainide Acetate [usp Impurity]
70. Ncgc00093934-01
71. Ncgc00093934-02
72. Ncgc00257762-01
73. As-11702
74. Flecainide Acetate [usp Monograph]
75. Hy-17429
76. Db-052497
77. Eu-0100546
78. Ft-0630667
79. En300-51344
80. D00638
81. E-0735
82. F 6777
83. 143f565
84. Sr-01000000172-2
85. Sr-01000000172-4
86. Sr-01000000172-5
87. Sr-01000000172-7
88. Q27089351
89. Flecainide Acetate, British Pharmacopoeia (bp) Reference Standard
90. Flecainide Acetate, European Pharmacopoeia (ep) Reference Standard
91. 2,5-bis(2,2,2-trifluoroethoxy)-n-(2-piperidylmethyl)benzamide Acetate
92. Flecainide Acetate, United States Pharmacopeia (usp) Reference Standard
93. 2-({[2,5-bis(2,2,2-trifluoroethoxy)benzoyl]amino}methyl)piperidinium Acetate
94. Flecainide For System Suitability, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 474.4 g/mol |
---|---|
Molecular Formula | C19H24F6N2O5 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 7 |
Exact Mass | 474.15894084 g/mol |
Monoisotopic Mass | 474.15894084 g/mol |
Topological Polar Surface Area | 96.9 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 531 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Flecainide acetate |
Drug Label | Flecainide acetate is an antiarrhythmic drug available in tablets of 50, 100, or 150 mg for oral administration. Flecainide acetate is benzamide, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. Its molecular formula is C17H20F6N2... |
Active Ingredient | Flecainide acetate |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 50mg; 150mg |
Market Status | Prescription |
Company | Ranbaxy; Amneal Pharm; Roxane; Barr |
2 of 2 | |
---|---|
Drug Name | Flecainide acetate |
Drug Label | Flecainide acetate is an antiarrhythmic drug available in tablets of 50, 100, or 150 mg for oral administration. Flecainide acetate is benzamide, N-(2-piperidinylmethyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. Its molecular formula is C17H20F6N2... |
Active Ingredient | Flecainide acetate |
Dosage Form | Tablet |
Route | Oral |
Strength | 100mg; 50mg; 150mg |
Market Status | Prescription |
Company | Ranbaxy; Amneal Pharm; Roxane; Barr |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2024
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InCarda Announces RESTORE-1 Phase 3 Trial Results and Continued Development Plans
Details : FlecIH-103 is a novel inhaled drug designed to rapidly deliver flecainide acetate, to the heart via the lungs to restore normal sinus rhythm in patient’s symptoms recurrent PAF.
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2024
Details:
Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: PhysIQ
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2022
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : PhysIQ
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Partnering with physIQ and Syneos Health has allowed to develop and execute a patient-centric strategy to support the Phase 3 program of orally inhaled flecainide (Inrhythm) for acute cardioversion of recent-onset AF.
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 24, 2022
Details:
Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 06, 2021
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm Program
Details : Based on these positive Phase 2 study results, along with recent interactions with the U.S. Food and Drug Administration (FDA), InCarda plans to conduct a single pivotal Phase 3 trial of InRhythm in patients with recent-onset PAF.
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2021
Details:
Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Deerfield Management
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Deerfield Management
Deal Size : $30.0 million
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : Proceeds from the financing will be used primarily to fund the ongoing clinical development of InRhythm™ (flecainide for inhalation), the company’s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation (PAF).
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 21, 2020
Details:
The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: InRhythm
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series C Financing October 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Innoviva
Deal Size : Undisclosed
Deal Type : Series C Financing
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
Details : The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.
Product Name : InRhythm
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 21, 2020
Details:
Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval for the US market.
Lead Product(s): Flecainide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2020
Lead Product(s) : Flecainide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Beximco Pharma Receives US FDA Approval for Antiarryhtmic Drug Flecainide
Details : Beximco received USFDA approval for Flecainide Acetate (50, 100 and 150 mg tablets), an antiarrythmic drug used for treating irregular heartbeats in conditions such as tachycardia and artrial fibrillation. This marks the Company's eighth product approval...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2020
CAS Number : 22990-77-8
End Use API : Flecainide
About The Company : Aurore Life Sciences is a pure-play API manufacturer with a diverse portfolio of capabilities in delivering efficiencies to generic players globally. Founded in...
2,5 Bis (2,2,2trifluoroethoxy) benzoic acid
CAS Number : 35480-52-5
End Use API : Flecainide
About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...
2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZOIC ACID
CAS Number : 35480-52-5
End Use API : Flecainide
About The Company : SURVIVAL is one of the leading manufacturers in the field of Fine and Specialty Chemicals actively involved in CRAMS, Custom Synthesis & Bulk Production offerin...
2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZOIC ACID
CAS Number : 35480-52-5
End Use API : Flecainide
About The Company : SURVIVAL is one of the leading manufacturers in the field of Fine and Specialty Chemicals actively involved in CRAMS, Custom Synthesis & Bulk Production offerin...
2,5-Bis(2,2,2-trifluoroethoxy)benzoic Acid
CAS Number : CAS-35480-52-5
End Use API : Flecainide
About The Company : Venkata Narayana Active Ingredients (Formerly Nutra Specialties Private Limited) Promoted by a well-known business house of India, Mr. Abhaya Kumar Jain who has...
Regulatory Info :
Registration Country : Italy
Brand Name : FLECAINIDE AUROBINDO
Dosage Form : Tablets 20 Tablets In Pvc/Pvdc/Al
Dosage Strength : 100 mg
Packaging : 20 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : FREQUIL
Dosage Form : Hard Capsules With Extended Release
Dosage Strength : 150 mg
Packaging : 30 UNITS 150 MG - ORAL USE (PROLONGED RELEASE)
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : RX
Registration Country : USA
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Packaging :
Approval Date : 2003-01-14
Application Number : 76278
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Tambocor CR 200
Dosage Form : CAP
Dosage Strength : 200mg
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Sweden
Brand Name : Tambocor Retard
Dosage Form : PROLONGED-RELEASE CAPSULE, HARD
Dosage Strength : 200 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Flecainid Sandoz
Dosage Form : Antic-calc Tablet
Dosage Strength : 100 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : FLECAINIDE SANDZ
Dosage Form : Tablets
Dosage Strength : 100 mg
Packaging : 20 UNITS 100 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : RX
Registration Country : USA
Brand Name : FLECAINIDE ACETATE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Packaging :
Approval Date : 2003-03-28
Application Number : 76421
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Sweden
Brand Name : Tambocor
Dosage Form : TABLET
Dosage Strength : 100 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Tambocor
Dosage Form : TABLET
Dosage Strength : 100 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
68
PharmaCompass offers a list of Flecainide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Flecainide manufacturer or Flecainide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Flecainide manufacturer or Flecainide supplier.
PharmaCompass also assists you with knowing the Flecainide API Price utilized in the formulation of products. Flecainide API Price is not always fixed or binding as the Flecainide Price is obtained through a variety of data sources. The Flecainide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tambocor manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tambocor, including repackagers and relabelers. The FDA regulates Tambocor manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tambocor API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tambocor manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tambocor supplier is an individual or a company that provides Tambocor active pharmaceutical ingredient (API) or Tambocor finished formulations upon request. The Tambocor suppliers may include Tambocor API manufacturers, exporters, distributors and traders.
click here to find a list of Tambocor suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tambocor DMF (Drug Master File) is a document detailing the whole manufacturing process of Tambocor active pharmaceutical ingredient (API) in detail. Different forms of Tambocor DMFs exist exist since differing nations have different regulations, such as Tambocor USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tambocor DMF submitted to regulatory agencies in the US is known as a USDMF. Tambocor USDMF includes data on Tambocor's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tambocor USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tambocor suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tambocor Drug Master File in Japan (Tambocor JDMF) empowers Tambocor API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tambocor JDMF during the approval evaluation for pharmaceutical products. At the time of Tambocor JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tambocor suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Tambocor Drug Master File in Korea (Tambocor KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tambocor. The MFDS reviews the Tambocor KDMF as part of the drug registration process and uses the information provided in the Tambocor KDMF to evaluate the safety and efficacy of the drug.
After submitting a Tambocor KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tambocor API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Tambocor suppliers with KDMF on PharmaCompass.
A Tambocor CEP of the European Pharmacopoeia monograph is often referred to as a Tambocor Certificate of Suitability (COS). The purpose of a Tambocor CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Tambocor EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Tambocor to their clients by showing that a Tambocor CEP has been issued for it. The manufacturer submits a Tambocor CEP (COS) as part of the market authorization procedure, and it takes on the role of a Tambocor CEP holder for the record. Additionally, the data presented in the Tambocor CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Tambocor DMF.
A Tambocor CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Tambocor CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Tambocor suppliers with CEP (COS) on PharmaCompass.
A Tambocor written confirmation (Tambocor WC) is an official document issued by a regulatory agency to a Tambocor manufacturer, verifying that the manufacturing facility of a Tambocor active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tambocor APIs or Tambocor finished pharmaceutical products to another nation, regulatory agencies frequently require a Tambocor WC (written confirmation) as part of the regulatory process.
click here to find a list of Tambocor suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tambocor as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tambocor API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tambocor as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tambocor and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tambocor NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tambocor suppliers with NDC on PharmaCompass.
Tambocor Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tambocor GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tambocor GMP manufacturer or Tambocor GMP API supplier for your needs.
A Tambocor CoA (Certificate of Analysis) is a formal document that attests to Tambocor's compliance with Tambocor specifications and serves as a tool for batch-level quality control.
Tambocor CoA mostly includes findings from lab analyses of a specific batch. For each Tambocor CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tambocor may be tested according to a variety of international standards, such as European Pharmacopoeia (Tambocor EP), Tambocor JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tambocor USP).